Kurs
-4,71%
Kurs
-4,71%
Open
705,00
High
728,00
Low
639,00
Close
648,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
3,77 MNOK
Likviditet
3,77 MNOK
Rel. mcap
1,30%
Antal aktier
5 568
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2026-02-12 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-29 | - | Årsstämma |
| 2025-04-24 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2025-04-01 | - | Split ZLNA 10:1 |
| 2025-01-31 | - | Bokslutskommuniké 2024 |
| 2025-01-09 | - | Extra Bolagsstämma 2025 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2024-04-24 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-21 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2023-04-20 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-21 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-22 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2021-04-21 | - | Årsstämma |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-11 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-16 | - | X-dag ordinarie utdelning ZLNA 0.00 NOK |
| 2020-04-15 | - | Årsstämma |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-05-10 17:00:00
Oslo, 10 May 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage
leader in immune stimulatory vaccines for cancer, today announced that its
management team will discuss data from the abstract of a poster presentation at
the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting at a series
of investor events in May, beginning with a live corporate webcast on Thursday
May 20, 2021.
The abstract is titled "A Phase I Clinical Trial Investigating the Telomerase
Vaccine UV1 in Combination with Pembrolizumab in Patients with Advanced
Melanoma". It provides an overview of the open-label, single-arm study
investigating the safety and tolerability for the combination of Ultimovacs'
universal cancer vaccine, UV1, with the checkpoint inhibitor pembrolizumab in
patients with metastatic malignant melanoma.
The ASCO abstract will be made available on the company website on Wednesday,
May 19th at 23:00 CEST and will be presented at the ASCO 2021 Annual Meeting to
be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The full
poster presentation from the ASCO Annual Meeting will be available on the
Ultimovacs website on 4 June 2021.
Details of the investor events:
Event: Live Corporate Webcast
Date/Time: Thursday May 20, 10:00 CEST
Presenter: Carlos de Sousa, CEO